|
|
|
|
|
PRESS RELEASE - 2002 |
 | |
October 2002
California Business Executive Chosen for China Trade Mission - BioGenex Laboratories, Inc. Part of U.S. Chamber of Commerce Delegation
July 2002
InnoGenex, a Subsidiary of BioGenex, Announces Complete, Ready-to-Use Immunohistochemistry Kits for Rodent Tissues
July 2002
BioGenex Introduces Total Walk Away Imaging System – The iVISION?
July 2002
BioGenex Announces Next Generation Staining Automated System – The i6000?
June 2002
BioGenex Introduces GenoMx? VISION Automated Imaging Analysis System
May 2002
InnoGenex, a Subsidiary of BioGenex, Introduces GeneXPROTM Outsourcing Contract Services for Gene Expression Profiling and Target Localization
May 2002
BioGenex Introduces Antibody Against Alpha-1-Antichymotrypsin, a Marker for Differential Diagnosis of Benign Hyperplasia and Prostate Cancer
May 2002
BioGenex Introduces Antibody against Ki67, a Marker for Studying Malignant Tumors and Other Pathogenic States as a Measure of Cell Proliferation
May 2002
BioGenex Introduces antibody against CDX2 Antibody, a Marker for Identifying Metastatic Colonic Carcinoma of Unknown Primary Tumor
May 2002
BioGenex Introduces Antibody Against Estrogen Receptor-Beta, a Marker for Breast Cancer Prognostics and Diagnostics
May 2002
InnoGenex, a Subsidiary of BioGenex, Introduces Universal In Situ Hybridization Detection Kits for All Tissues
May 2002
BioGenex Introduces Antibody Against Osteonectin, a Biochemical Marker for Bone-Related Tumors
May 2002
InnoGenex, a Subsidiary of BioGenex, Introduces Tissue Microarrays for High-Throughput Screening of In Situ Gene Expression Analysis
April 2002
InnoGenex, a Subsidiary of BioGenex, Introduces Complete, Ready-to-Use In Situ Hybridization Kits
April 2002
InnoGenex, a Subsidiary of BioGenex, Announces the Iso-IHC Kit for Mouse Antibodies on Mouse Tissues with No Background
April 2002
BioGenex Introduces Osteocalcin Antibody for Differential Diagnosis of Osteosarcoma
April 2002
BioGenex Announces the First World Automated Antigen Retrieval System – The i1000™
March 2002
BioGenex Obtains FDA Clearance to Market ER and PR Automated Immunohistochemistry Assays for Diagnosis and Management of Primary Breast Cancer
|
|
